Companies ›Healthcare ›MDCX.O

MDCX.O — NASDAQ Pharmaceuticals

Medicus Pharma Ltd

$0,31

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

17,6M USD

P/E

—

EV / Rev

—

Div yield

—

Op margin

—

ROE

-56,3 %

Net margin

—

Debt / equity

0,06

Beta

—

52w range

—

Volume

34,6k

Day range

—

Prev close

$0,31

Open

—

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

Medicus Pharma Ltd is a biotechnology company focused on the development and commercialization of innovative pharmaceutical products, primarily in the healthcare sector.

Business. Medicus Pharma Ltd (MDCX.O) is a pharmaceutical company operating within the Healthcare sector, specifically engaged in pharmaceuticals and medical research. The firm generates revenue through product sales and is primarily listed on the NASDAQ exchange. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryPharmaceuticals

Generated · model-assisted

Sell-side consensus

BUY4 analysts

4 buy0 hold0 sell

Avg 12m price target6,50

Analyst recommendations

4 analysts · consensus Buy

Buy4

Hold0

Sell0

12-month price target

6,50

Consensus of sell-side coverage.

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

4 analysts · indicative

Ownership→

UBS Financial Services, Inc.

largest disclosed fund holder

Profitability→

-56,3 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning MDCX.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to MDCX.O. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Medicus Pharma Ltd (MDCX.O) is a pharmaceutical company operating within the Healthcare sector, specifically engaged in pharmaceuticals and medical research. The firm generates revenue through product sales and is primarily listed on the NASDAQ exchange. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryPharmaceuticals

AI synthesis

GENERATED

Medicus Pharma operates with a total equity of $6.45 million and a total asset base of $8.78 million, indicating a relatively strong capital structure. The company's debt-to-equity ratio is 0.06, suggesting minimal leverage and a conservative approach to financing. However, the company's liquidity position is rated as medium, and its operating cash flow is negative at -$3.95 million, which raises concerns about its ability to fund operations without external financing.

The company's profitability metrics are concerning, with a return on equity of -56.31% and a return on assets of -41.37%. These figures indicate that the company is not generating returns for its shareholders and is underperforming in terms of asset utilization. The net income is negative at -$3.63 million, and the operating income is also negative at -$3.55 million, reflecting ongoing operational challenges.

Medicus Pharma's revenue concentration and geographic exposure are not explicitly detailed in the available data. However, the company's operations are primarily focused on the biotechnology segment, which is a high-growth but capital-intensive industry. The lack of detailed segment and geographic data limits the ability to assess diversification risks.

The company's growth trajectory is uncertain, with no specific revenue growth projections provided. The current market price of $0.337 is significantly below the mean and median analyst price targets of $6.50 and $7.50, respectively, indicating a potential for upward revaluation if the company can address its operational and financial challenges. The price-to-book ratio of 2.96 suggests that the market is valuing the company at a premium to its book value, which may not be justified given the current financial performance.

The risk assessment highlights liquidity as a medium concern, with the company's net cash position being negative after accounting for total debt. The dilution risk is rated as low, but the company's negative operating cash flow and high price-to-book ratio suggest that it may need to raise additional capital, which could lead to share dilution. The current ratio of 4.11 indicates that the company has sufficient current assets to cover its current liabilities, which is a positive sign for short-term liquidity.

Recent events and filings do not provide specific details on the company's strategic initiatives or operational changes. However, the significant gap between the current market price and analyst price targets suggests that there may be positive developments or expectations that are not yet reflected in the stock price.

Key takeaways

Medicus Pharma has a strong equity base but is experiencing negative operating and net income, indicating operational inefficiencies.
The company's liquidity position is medium, and its negative operating cash flow raises concerns about its ability to fund operations without external financing.
The price-to-book ratio is high at 2.96, suggesting the market is valuing the company at a premium to its book value, which may not be justified given the current financial performance.
Analysts have set a mean price target of $6.50, significantly higher than the current market price of $0.337, indicating potential for upward revaluation if the company can address its challenges.
The company's risk assessment highlights liquidity as a medium concern, with the need for additional capital potentially leading to share dilution.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Quarterly

Annual

QUARTERLYFiled 2026-05-14

Q1 2026 · Quarter highlights

Open report →

Revenue—

Operating income—

Net income—

Free cash flow—

EPS—

Operating cash flow-$9.0M−127,6 % YoY

Financials

Balance sheet

Total assets—

Total liabilities$6.1M

Total equity$1.3M

Cash & equivalents$6.4M

Long-term debt$2.4M

Cash flow

Operating cash flow-$9.0M

CapEx—

Free cash flow—

SBC—

Valuation TTM

Market price

$0,31

Market cap

$19.1M

Enterprise valueⓘ

$19.5M

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

3.0x

P / Tangible bookⓘ

3.0x

Tangible book

$6.5M

Net cashⓘ

-$375.0k

Current ratioⓘ

4.1

Debt / equityⓘ

0.1

ROAⓘ

-41.4%

ROEⓘ

-56.3%

Cash conversionⓘ

109.0%

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

-0,58

Predicted surprise

+0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

revision ratio 0,00 · as of 2026-05-17 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	-0,58
Revenue	—no estimate	—no estimate	0 USD
Operating income	—no estimate	—no estimate	-26,4M USD

Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution4 analysts

Strong buy0

Buy4

Hold0

Sell0

Strong sell0

12-month price target$6,50 · Median $7,50

Low $2,00High $9,00

Operating income · consensus-26,4M USD

EPS surprise

−368,4 %

reported vs consensus · miss

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$2,00

Mean$6,50

Median$7,50

High$9,00

Spot$0,31

+1996.8 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskMedium

Filing-based flags

Net cash is negative after subtracting total debt.

Benchmarks vs cohort

ROE-56,3 %Bottom quartile

D/E0,06Above median

Cash Conv1,09Above median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net acquired 2 425 000 sh25 grants13 insiders

Kaiser LarryDirector · Stock Option (right to buy) → Common SharesAcquired 50 000 @ $0,36grant · 2026-06-03
Smith Andrew AlasdairChief Operating Officer · Stock Option (right to buy) → Common SharesAcquired 200 000 @ $0,36grant · 2026-06-03
MAHAFFY PATRICK JDirector · Stock Option (right to buy) → Common SharesAcquired 50 000 @ $0,36grant · 2026-06-03
May Sara R.Director · Stock Option (right to buy) → Common SharesAcquired 50 000 @ $0,36grant · 2026-06-03
Mehmud FaisalChief Medical Officer · Stock Option (right to buy) → Common SharesAcquired 250 000 @ $0,36grant · 2026-06-03
Raju AjayDirector · Stock Option (right to buy) → Common SharesAcquired 50 000 @ $0,36grant · 2026-06-03
Rodgers Cathy McMorrisDirector · Stock Option (right to buy) → Common SharesAcquired 50 000 @ $0,36grant · 2026-06-03
FISHMAN BARRYDirector · Stock Option (right to buy) → Common SharesAcquired 50 000 @ $0,36grant · 2026-06-03
Ashton WilliamDirector · Stock Option (right to buy) → Common SharesAcquired 50 000 @ $0,36grant · 2026-06-03
Bokhari RazaDirector, Chief Executive Officer · Stock Option (right to buy) → Common SharesAcquired 500 000 @ $0,36grant · 2026-06-03
Bonner Carolyn F.President and CFO · Stock Option (right to buy) → Common SharesAcquired 250 000 @ $0,36grant · 2026-06-03
Brennan Edward J.Chief Scientific Officer · Stock Option (right to buy) → Common SharesAcquired 25 000 @ $0,36grant · 2026-06-03
Ciaruffoli Robert J.Director · Stock Option (right to buy) → Common SharesAcquired 50 000 @ $0,36grant · 2026-06-03
Raju AjayDirector · Stock Option (right to buy) → Common SharesAcquired 25 000 @ $0,50grant · 2026-03-30
Smith Andrew AlasdairChief Operating Officer · Stock Option (right to buy) → Common SharesAcquired 50 000 @ $0,50grant · 2026-03-30
Rodgers Cathy McMorrisDirector · Stock Option (right to buy) → Common SharesAcquired 25 000 @ $0,50grant · 2026-03-30
Bokhari RazaDirector, Chief Executive Officer · Stock Option (right to buy) → Common SharesAcquired 325 000 @ $0,50grant · 2026-03-30
Brennan Edward J.Chief Scientific Officer · Stock Option (right to buy) → Common SharesAcquired 25 000 @ $0,50grant · 2026-03-30
Ciaruffoli Robert J.Director · Stock Option (right to buy) → Common SharesAcquired 25 000 @ $0,50grant · 2026-03-30
FISHMAN BARRYDirector · Stock Option (right to buy) → Common SharesAcquired 25 000 @ $0,50grant · 2026-03-30
Kaiser LarryDirector · Stock Option (right to buy) → Common SharesAcquired 25 000 @ $0,50grant · 2026-03-30
MAHAFFY PATRICK JDirector · Stock Option (right to buy) → Common SharesAcquired 25 000 @ $0,50grant · 2026-03-30
May Sara R.Director · Stock Option (right to buy) → Common SharesAcquired 25 000 @ $0,50grant · 2026-03-30
Mehmud FaisalChief Medical Officer · Stock Option (right to buy) → Common SharesAcquired 125 000 @ $0,50grant · 2026-03-30
Bonner Carolyn F.President and CFO · Stock Option (right to buy) → Common SharesAcquired 100 000 @ $0,50grant · 2026-03-30

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Return On Equity
net_income / total_equity
Price To Book
market_price / (adjusted_book_value / shares_outstanding_diluted)
Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Market Price
input from market-data provider (delayed close or quote-shim mid)
Market Cap
market_price * shares_outstanding_diluted
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt

Source documents

Medicus Pharma Ltd Market data — financials · 2026-05-28
Medicus Pharma Ltd Market data — analyst estimates · 2026-05-28

Ownership & reference

Top holders

UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$0M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M
JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M

Insider activity

— missing data

Short positioning

2.8Mshares short+171.5% vs prior

2.48days to cover

56.9%short of daily vol

39.4Kfails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

MDCX.OCanonical

NASDAQ · USD

Intel & risk

PredictorBeat prob45 %Surprise+0,00Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskMedium

Net cash is negative after subtracting total debt.

Evidence & claims

From filings & derived data

R&D expense (YoY) (2025-12-31 vs 2024-12-31): 118.9%Derived (calculated)
Net income (YoY) (2025-12-31 vs 2024-12-31): -323.8%Derived (calculated)
Return on equity (FY 2025-12-31): 69,990.7%Derived (calculated)
Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -122.3%Derived (calculated)
Return on assets (FY 2025-12-31): -469.9%Derived (calculated)
Operating income (YoY) (2025-12-31 vs 2024-12-31): -207.3%Derived (calculated)
Current ratio (FY 2025-12-31): 1.00xDerived (calculated)
Debt-to-equity (FY 2025-12-31): -148.39xDerived (calculated)
Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 299.0%Derived (calculated)
Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 109.0%Derived (calculated)
EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -136.2%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -102.2%Derived (calculated)
Total assets (YoY) (2025-12-31 vs 2024-12-31): 78.2%Derived (calculated)
EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -136.2%Derived (calculated)
Total operating expenses (annual): USD 34.36MSEC XBRL filing
Total assets (annual): USD 10.06MSEC XBRL filing
Operating cash flow (annual): USD -22.78MSEC XBRL filing
Shareholders' equity (annual): USD -67.55KSEC XBRL filing
Shares outstanding (annual): 25.18MSEC XBRL filing
Cash & equivalents (annual): USD 8.71MSEC XBRL filing
Current liabilities (annual): USD 9.94MSEC XBRL filing
Total liabilities (annual): USD 10.02MSEC XBRL filing
Current assets (annual): USD 9.89MSEC XBRL filing
Net income (annual): USD -47.28MSEC XBRL filing

Showing 24 of 60 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-07-29 22:34 UTCEVENTHa Price Listing MDCX remains DEFICIENT (NASDAQ) — cure period. closed below $1.00 for 97 consecutive trading days (last close $0.3998). cure deadline 2027-01-17 (172 days remaining).

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2026-06-04FILINGFORM 424B3 →

2026-06-04FILINGFORM 8-K →

2026-06-03 00:00 UTCINSIDER13 insider transactions — 2026-06 13 derivative

2026-06-03INSIDERRodgers Cathy McMorris acquired 50.0k sh Stock Option (right to buy) — Director

2026-06-03INSIDERMehmud Faisal acquired 250.0k sh Stock Option (right to buy) — Chief Medical Officer

2026-06-03INSIDERMay Sara R. acquired 50.0k sh Stock Option (right to buy) — Director

2026-06-03INSIDERMAHAFFY PATRICK J acquired 50.0k sh Stock Option (right to buy) — Director

2026-06-03INSIDERKaiser Larry acquired 50.0k sh Stock Option (right to buy) — Director

2026-06-03INSIDERFISHMAN BARRY acquired 50.0k sh Stock Option (right to buy) — Director

2026-06-03INSIDERCiaruffoli Robert J. acquired 50.0k sh Stock Option (right to buy) — Director

2026-06-03INSIDERBrennan Edward J. acquired 25.0k sh Stock Option (right to buy) — Chief Scientific Officer

2026-06-03INSIDERBonner Carolyn F. acquired 250.0k sh Stock Option (right to buy) — President and CFO

2026-06-03INSIDERBokhari Raza acquired 500.0k sh Stock Option (right to buy) — Director, Chief Executive Officer

2026-06-03INSIDERAshton William acquired 50.0k sh Stock Option (right to buy) — Director

2026-06-03INSIDERSmith Andrew Alasdair acquired 200.0k sh Stock Option (right to buy) — Chief Operating Officer

2026-06-03INSIDERRaju Ajay acquired 50.0k sh Stock Option (right to buy) — Director

2026-05-28FILINGFORM 424B3 →

2026-05-27FILINGFORM 8-K →

2026-05-14 16:13 UTCEARNINGSQuarterly results — Q1 2026

2026-05-14FILINGFORM 424B3 →

2026-05-14FILINGFORM 10-Q →

2026-05-04FILINGFORM DEF 14A →

2026-04-30FILINGFORM 424B3 →

2026-04-27FILINGFORM 424B3 →

2026-04-24FILINGFORM 8-K →

2026-04-23FILINGFORM 424B3 →

2026-03-30 00:00 UTCINSIDER12 insider transactions — 2026-03 12 derivative

2026-03-30INSIDERRodgers Cathy McMorris acquired 25.0k sh Stock Option (right to buy) — Director

2026-03-30INSIDERSmith Andrew Alasdair acquired 50.0k sh Stock Option (right to buy) — Chief Operating Officer

2026-03-30INSIDERRaju Ajay acquired 25.0k sh Stock Option (right to buy) — Director

2026-03-30INSIDERCiaruffoli Robert J. acquired 25.0k sh Stock Option (right to buy) — Director

2026-03-30INSIDERBokhari Raza acquired 325.0k sh Stock Option (right to buy) — Director, Chief Executive Officer

2026-03-30INSIDERBonner Carolyn F. acquired 100.0k sh Stock Option (right to buy) — President and CFO

2026-03-30INSIDERBrennan Edward J. acquired 25.0k sh Stock Option (right to buy) — Chief Scientific Officer

2026-03-30INSIDERMehmud Faisal acquired 125.0k sh Stock Option (right to buy) — Chief Medical Officer

2026-03-30INSIDERMay Sara R. acquired 25.0k sh Stock Option (right to buy) — Director

2026-03-30INSIDERMAHAFFY PATRICK J acquired 25.0k sh Stock Option (right to buy) — Director

Showing the 40 most recent of 50 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation TTM

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread